Nissay Asset Management Corp Japan ADV Has $6.56 Million Stake in DexCom, Inc. $DXCM

Key Points

• Nissay Asset Management Corp Japan ADV increased its stake in DexCom, Inc. by 8.5%, owning 96,075 shares valued at approximately $6.56 million.
• DexCom reported earnings of $0.48 per share for the recent quarter, exceeding expectations and showing a 15.2% revenue increase compared to the previous year.
• Analysts have a consensus rating of "Moderate Buy" for DexCom, with a target price around $99.89, reflecting confidence in the company’s stock performance.

Nissay Asset Management Corp Japan ADV lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 8.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 96,075 shares of the medical device company's stock after purchasing an additional 7,497 shares during the period. Nissay Asset Management Corp Japan ADV's holdings in DexCom were worth $6,561,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Golden State Wealth Management LLC grew its position in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom during the 1st quarter worth approximately $27,000. Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth approximately $38,000. Alpine Bank Wealth Management acquired a new stake in shares of DexCom during the 1st quarter worth approximately $40,000. Finally, Private Trust Co. NA grew its position in shares of DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after buying an additional 335 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Down 0.3%

DexCom stock opened at $80.51 on Friday. The company's 50 day simple moving average is $81.58 and its 200 day simple moving average is $79.07. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm has a market capitalization of $31.57 billion, a price-to-earnings ratio of 55.91, a PEG ratio of 1.69 and a beta of 1.48. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm earned $0.43 EPS. DexCom's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the transaction, the director owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. The trade was a 9.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the transaction, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 15,722 shares of company stock worth $1,306,131. Corporate insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the subject of several analyst reports. Mizuho lifted their price target on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Citigroup reiterated a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Barclays lifted their price target on shares of DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Raymond James Financial lifted their price target on shares of DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 31st. Finally, William Blair raised shares of DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.